diphtheria & tetanus toxoids (Rx)

  • Print
Brand and Other Names:Decavac, Tenivac, more...Td, DT

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

Lf (flocculation units)

diphtheria/tetanus toxoid

suspension

  • (2Lf/2Lf)/0.5mL
  • (2Lf/5Lf)/0.5mL (Tenivac)

diphtheria/tetanus toxoid absorbed

suspension

  • (25Lf/5Lf)/0.5mL
more...

Primary Immunization

Tenivac (not previously immunized): 2 primary doses of 0.5 mL IM each given at an interval of 4 weeks with a third dose (0.5 mL) 6 months later

Booster Immunization

0.5 mL every 10 years (patients that have completed primary immunization)

Dosage Forms & Strengths

Lf (flocculation units)

diphtheria/tetanus toxoid

suspension

  • (2Lf/2Lf)/0.5mL(2Lf/5Lf)/0.5mL

diphtheria/tetanus toxoid absorbed

suspension

  • (25Lf/5Lf)/0.5mL
more...

Primary Immunization

For use if pertussis component contraindicated; DTaP preferred for primary immunization

<7 years

  • Three doses: 0.5 mL (DT) at 2, 4, and 6 months of age; may administer as early as 6 weeks of age and repeated every 4-8 weeks
  • Fourth dose: At least 6 months must elapse between the third and fourth dose; may give as early as 12 months of age if 6 months have passed since the third dose
  • Fifth dose: 4-6 years of age prior to starting school or kindergarten; may omit this dose if fourth dose given >4 years of age

>7 years

  • Tanivac (not previously immunized): 2 primary doses of 0.5 mL IM each given at an interval of 4 weeks with a third dose (0.5 mL) 6 months later

Booster Immunization

0.5 mL every 10 years (patients that have completed primary immunization)

Next:

Interactions

Interaction Checker

and diphtheria & tetanus toxoids

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967

            >10%

            Headache (34-40%)

            Tiredness (21-27%)

            Chills (7-13%)

            Diarrhea (10-11%)

            Nausea (8-12%)

            Swelling (17-18%)

            Sore/swollen joints (7-12%)

            Tenderness, pain, redness, swelling at inj site (63%)

            Arthus reaction (rare)

            1-10%

            Rash (2%)

            Lymph node swelling (4-5%)

            Fever (1-3%)

            Vomiting (2-3%)

            <1%

            Myalgia

            Paresthesia

            Seizure

            Chils

            Dizziness

            Fatigue

            Lymphadenopathy

            Musculosckeletal stiffness

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity to toxoids or any component of the formulation

            Cautions

            Treatment (including epinephrine 1:1000) for anaphylactoid/hypersensitivity reactions should be present during vaccine use

            Not for administration more frequently than every 10 years in patients who experienced a serious arthus-type hypersensitivity reaction following a prior use of tetanus toxoid vaccine even if using for wound management

            Syncope, transient visual disturbances, tonic-clonic movements, or weakness reported with use

            Use caution if Ghillain-Barre syndrome occurs within 6 weeks of tetanus toxoid administration

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Excretion in milk unknown; use with caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Toxoid stimulation of active immunity

            Pharmacokinetics

            The onset of protection from disease is relatively slow, but duration is long lasting (years)

            Duration >10 yr

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous